Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, r...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/3094642 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229145797132288 |
|---|---|
| author | Young-Sun Lee Hee-Sook Jun |
| author_facet | Young-Sun Lee Hee-Sook Jun |
| author_sort | Young-Sun Lee |
| collection | DOAJ |
| description | Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action. |
| format | Article |
| id | doaj-art-27fda4c66da54316b77b64f46ee0c55b |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-27fda4c66da54316b77b64f46ee0c55b2025-08-20T02:04:19ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/30946423094642Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlYoung-Sun Lee0Hee-Sook Jun1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of KoreaLee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of KoreaGlucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.http://dx.doi.org/10.1155/2016/3094642 |
| spellingShingle | Young-Sun Lee Hee-Sook Jun Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control Mediators of Inflammation |
| title | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| title_full | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| title_fullStr | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| title_full_unstemmed | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| title_short | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| title_sort | anti inflammatory effects of glp 1 based therapies beyond glucose control |
| url | http://dx.doi.org/10.1155/2016/3094642 |
| work_keys_str_mv | AT youngsunlee antiinflammatoryeffectsofglp1basedtherapiesbeyondglucosecontrol AT heesookjun antiinflammatoryeffectsofglp1basedtherapiesbeyondglucosecontrol |